Urology
Data suggest darifenacin is efficacious treatment for overactive bladder
Published in Women's Health Weekly, August 26th, 2004
"Darifenacin is a muscarinic antagonist in Phase III clinical trials for the treatment of overactive bladder (OAB). Darifenacin demonstrates relative selectivity for the M-3 muscarinic receptor subtype over the M-1 and M-2 subtypes. In clinical trials, darifenacin has been compared to placebo for the treatment of symptoms of OAB in adult men and women," investigators in the United States report.
"Patients treated with darifenacin experienced significantly greater reductions in the number of incontinence episodes per week,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Aerobic Vaginitis
Study: Intravaginal kanamycin more effective treatment than meclocycline - Breast Cancer
Adherence to treatment guidelines improves early breast cancer survival - Breast Cancer
Few U.S. surgeons doing enough operations to optimize outcomes - Breast Cancer
p53 mutation more prevalent in African American women - Hormone Replacement Therapy
"One size does not fit all" approach recommended for HRT in menopause - Adolescent Health
Many adolescent girls experience headache, stomachache, back pain and fatigue - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
